Relacorilant in recurrent ovarian cancer: clinical evidence and future perspectives

References

• Moore KN, Angelergues A, Konecny GE, et al. Mirvetuximab Soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med. 2023;389(23):2162–2174. doi: 10.1056/NEJMoa2309169
   PubMed Web of Science ®Google Scholar
• Ghose A, Gullapalli SVN, Chohan N, et al. Applications of proteomics in ovarian cancer: Dawn of a new era. Proteomes. 2022;10(2):16. doi: 10.3390/proteomes10020016
   PubMed Web of Science ®Google Scholar
• Ortiz M, Wabel E, Mitchell K, et al. Mechanisms of chemotherapy resistance in ovarian cancer. Cancer Drug Resist. 2022;5:304–316. doi: 10.20517/cdr.2021.147
   PubMedGoogle Scholar
• Skor MN, Wonder EL, Kocherginsky M, et al. Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. Clin Cancer Res. 2013;19(22):6163–6172. doi: 10.1158/1078-0432.CCR-12-3826
   PubMed Web of Science ®Google Scholar
• Veneris JT, Darcy KM, Mhawech-Fauceglia P, et al. High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol. 2017;146(1):153–160. doi: 10.1016/j.ygyno.2017.04.012
   PubMed Web of Science ®Google Scholar
• Isikbay M, Otto K, Kregel S, et al. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014;5(2):72–89. doi: 10.1007/s12672-014-0173-2
   PubMed Web of Science ®Google Scholar
• Greenstein AE, Hunt HJ. Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells. Oncotarget. 2021;12(13):1243–1255. doi: 10.18632/oncotarget.27989
   PubMedGoogle Scholar
• Gruver-Yates AL, Cidlowski JA. Tissue-specific actions of glucocorticoids on apoptosis: a double-edged sword. Cells. 2013;2(2):202–223. doi: 10.3390/cells2020202
   PubMedGoogle Scholar
• Longui CA, Santos MC, Formiga CB, et al. Antiproliferative and apoptotic potencies of glucocorticoids: nonconcordance with their antiinflammatory and immunosuppressive properties. Arq Bras Endocrinol Metabol. 2005;49(3):378–383. doi: 10.1590/S0004-27302005000300008
   PubMedGoogle Scholar
• Goyeneche AA, Carón RW, Telleria CM. Mifepristone inhibits ovarian cancer cell growthIn vitro and in vivo mifepristone inhibits ovarian cancer cell growth in vitro and in vivo. Clin Cancer Res. 2007;13(11):3370–3379. doi: 10.1158/1078-0432.CCR-07-0164
   PubMed Web of Science ®Google Scholar
• Stringer-Reasor EM, Baker GM, Skor MN, et al. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015;138(3):656–662. doi: 10.1016/j.ygyno.2015.06.033
   PubMed Web of Science ®Google Scholar
• Melhem A, Yamada SD, Fleming GF, et al. Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues. Clin Cancer Res. 2009;15(9):3196–3204. doi: 10.1158/1078-0432.CCR-08-2131
   PubMed Web of Science ®Google Scholar
• Buonaiuto R, Neola G, Cecere SC, et al. Glucocorticoid receptor and ovarian cancer: from biology to therapeutic intervention. Biomolecules. 2023;13(4):653. doi: 10.3390/biom13040653
   PubMed Web of Science ®Google Scholar
• Rocereto TF, Saul HM, Aikins JA, et al. Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol Oncol. 2000;77(3):429–432. doi: 10.1006/gyno.2000.5789
   PubMed Web of Science ®Google Scholar
• Rocereto TF, Brady WE, Shahin MS, et al. A phase II evaluation of mifepristone in the treatment of recurrent or persistent epithelial ovarian, fallopian or primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2010;116(3):332–334. doi: 10.1016/j.ygyno.2009.10.071
   PubMed Web of Science ®Google Scholar
• Karvonen H, Arjama M, Kaleva L, et al. Glucocorticoids induce differentiation and chemoresistance in ovarian cancer by promoting ROR1-mediated stemness. Cell Death Dis. 2020;11(9):790. doi: 10.1038/s41419-020-03009-4
   PubMed Web of Science ®Google Scholar
• Bakour N, Moriarty F, Moore G, et al. Prognostic significance of glucocorticoid receptor expression in cancer: a systematic review and Meta-analysis. Cancers (Basel). 2021;13(7):1649. doi: 10.3390/cancers13071649
   PubMed Web of Science ®Google Scholar
• Chen N, Saha P, Rampurwala MM, et al. A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer. JCO. 2023;41(16_suppl):e13103–e13103. doi: 10.1200/JCO.2023.41.16_suppl.e13103
   Web of Science ®Google Scholar
• ORIC Pharmaceuticals Reports Fourth Quarter and Full Year. Financial results and operational update | ORIC pharmaceuticals, inc. [Internet]. 2021 [cited 2024 Jan 21]. Available from: https://investors.oricpharma.com/news-releases/news-release-details/oric-pharmaceuticals-reports-fourth-quarter-and-full-year-2021/
   Google Scholar
• Colombo N, Van Gorp T, Matulonis UA, et al. Relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer: a three-arm, randomized, controlled, Open-label phase II study. J Clin Oncol. 2023;41(30):4779–4789. doi: 10.1200/JCO.22.02624
   PubMed Web of Science ®Google Scholar
• University of Chicago. A randomized phase II trial of neoadjuvant enzalutamide plus the glucocorticoid receptor antagonist relacorilant versus placebo for patients with high-risk localized prostate cancer [internet]. Clinicaltrials.gov. 2023 [cited 2024 Jan 1]. ( Report No.: NCT05726292). Available from: https://clinicaltrials.gov/study/NCT05726292
   Google Scholar
• Hunt HJ, Belanoff JK, Walters I, et al. Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): a selective glucocorticoid receptor (GR) antagonist. J Med Chem. 2017;60(8):3405–3421. doi: 10.1021/acs.jmedchem.7b00162
   PubMed Web of Science ®Google Scholar
• Lorusso D, Bagameri A, Bishop E, et al. #205 ROSELLA (GOG-3073, ENGOT-Ov72/MITO): a phase 3 study of relacorilant + nab-paclitaxel vs. nab-paclitaxel in advanced, platinum-resistant ovarian cancer. Int J Gynecologic Cancer [Internet]. 2023 [cited 2024 Jan 21];33. Available from: https://ijgc.bmj.com/content/33/Suppl_3/A411.2
   Google Scholar
• Hunt H, Donaldson K, Strem M, et al. Assessment of safety, tolerability, pharmacokinetics, and pharmacological effect of orally administered CORT125134: an adaptive, double‐blind, randomized, placebo‐controlled phase 1 clinical study. Clin Pharmacol Drug Dev. 2018;7(4):408–421. doi: 10.1002/cpdd.389
   PubMed Web of Science ®Google Scholar
• Munster PN, Greenstein AE, Fleming GF, et al. Overcoming taxane resistance: preclinical and phase 1 studies of relacorilant, a selective glucocorticoid receptor modulator, with Nab-paclitaxel in solid tumors. Clin Cancer Res. 2022;28(15):3214–3224. doi: 10.1158/1078-0432.CCR-21-4363
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA Open-label randomized phase III trial. JCO. 2014;32(13):1302–1308. doi: 10.1200/JCO.2013.51.4489
   PubMed Web of Science ®Google Scholar
• Van Gorp T, Sabatier R, Konecny GE, et al. Efficacy of mirvetuximab soravtansine in folate receptor alpha high, platinum-resistant ovarian cancer by type and number of prior treatment regimens: an exploratory analysis. In: Presented at the 2023 Annual Global Meeting of the International Gynecologic Cancer Society (IGCS); 2023 Nov 5–7; Seoul, South Korea.
   Google Scholar